<DOC>
	<DOCNO>NCT03067753</DOCNO>
	<brief_summary>Monosialoganglioside Ganglioside Cerebral Radiation Necrosis</brief_summary>
	<brief_title>Monosialoganglioside Ganglioside Cerebral Radiation Necrosis</brief_title>
	<detailed_description>A prospective phase II trial conduct test efficacy monosialoganglioside ganglioside treatment cerebral radiation necrosis</detailed_description>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Undergone one course definitive radiotherapy histologically confirm nasopharyngeal carcinoma year ; At least two consecutive MRI study support diagnosis cerebral radiation necrosis ( CRN ) interval 34 month , second MRI show progressive disease compare first MRI ; Progressive neurologic symptom sign ; Minimental status examination ( MMSE ) score must ≤27 ; Karnofsky performance status≥70 ; Supposed live 6 month . After second course radiotherapy recurrent nasopharyngeal carcinoma ; Local regional relapse , distant metastasis ; Cerebrovascular disease ; Second primary malignancy ; Diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>